Phaseline

Targets › LY6E

LY6E (Lymphocyte antigen 6E): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2028.

GPI-anchored cell surface protein that regulates T-lymphocytes proliferation, differentiation, and activation. Regulates the T-cell receptor (TCR) signaling by interacting with component CD3Z/CD247 at the plasma membrane, leading to CD3Z/CD247 phosphorylation modulation (By similarity). (UniProt, Q16553)

Open in Phaseline: the race on LY6E, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Merck KGaAM7437
anti-Ly6E antibody-drug conjugate with exatecan payload
LY6EPhase 1Advanced Solid TumorsSep 2028

Conditions

Advanced Solid Tumors (1)

Modalities

small molecule (1)

Companies

Merck KGaA (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.